Startups
OpenAI, Thrive Capital Back Six-Month-Old AI Drug Discovery Startup
- Chai Discovery raised nearly $30 million in a new seed round
- Startup’s foundation model seeks to rival Google DeepMind
This article is for subscribers only.
Chai Discovery, an artificial intelligence biology startup founded six months ago, has raised nearly $30 million from heavyweights Thrive Capital and OpenAI to bring AI to drug discovery.
Chai develops AI foundation models that can predict the structure of biochemical molecules and reprogram how they interact, a process that is central to developing new medications. “We want to turn biology from a science into engineering,” said co-founder and Chief Executive Officer Joshua Meier.